Enlarge / Vials with COVID-19 vaccine labels showing logos of pharmaceutical company Pfizer and German biotechnology company BioNTech.Getty | Photonews
An advisory committee for the Food and Drug Administration on Thursday voted unanimously (21 to 0) to recommend updating COVID-19 vaccines for the 2023-2024 period to be a monovalent formula targeting the latest omicron subvariant lineage of XBB. Such an update would apply to both primary series shots as well as boosters.
The monovalent update means that the next COVID-19 vaccines will only target one version of pandemic coronaviruses. This is a switch from the current formula, which is bivalent,
→ Continue reading at Ars Technica